- Home
- CELC vs NNOX Comparison
CELC vs NNOX Comparison
Compare CELC & NNOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- NNOX
- Stock Information
- Founded
- CELC 2011
- NNOX 2011
- Country
- CELC United States
- NNOX Israel
- Employees
- CELC N/A
- NNOX N/A
- Industry
- CELC Medical Specialities
- NNOX Medical Electronics
- Sector
- CELC Health Care
- NNOX Health Care
- Exchange
- CELC Nasdaq
- NNOX Nasdaq
- Market Cap
- CELC 327.3M
- NNOX 330.6M
- IPO Year
- CELC 2017
- NNOX 2020
- Fundamental
- Price
- CELC $11.62
- NNOX $5.23
- Analyst Decision
- CELC Strong Buy
- NNOX Strong Buy
- Analyst Count
- CELC 5
- NNOX 2
- Target Price
- CELC $30.80
- NNOX $9.50
- AVG Volume (30 Days)
- CELC 148.5K
- NNOX 912.2K
- Earning Date
- CELC 05-14-2025
- NNOX 05-22-2025
- Dividend Yield
- CELC N/A
- NNOX N/A
- EPS Growth
- CELC N/A
- NNOX N/A
- EPS
- CELC N/A
- NNOX N/A
- Revenue
- CELC N/A
- NNOX $11,545,000.00
- Revenue This Year
- CELC N/A
- NNOX $105.67
- Revenue Next Year
- CELC N/A
- NNOX $177.95
- P/E Ratio
- CELC N/A
- NNOX N/A
- Revenue Growth
- CELC N/A
- NNOX 15.32
- 52 Week Low
- CELC $7.58
- NNOX $3.75
- 52 Week High
- CELC $19.77
- NNOX $11.00
- Technical
- Relative Strength Index (RSI)
- CELC 64.24
- NNOX 49.72
- Support Level
- CELC $10.50
- NNOX $4.97
- Resistance Level
- CELC $10.88
- NNOX $5.62
- Average True Range (ATR)
- CELC 0.62
- NNOX 0.29
- MACD
- CELC 0.05
- NNOX -0.03
- Stochastic Oscillator
- CELC 90.17
- NNOX 40.57
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About NNOX NANO-X IMAGING LTD
Nano X Imaging Ltd is engaged in the business of manufacturing medical imaging systems. It offers a Nanox System which is a combination of hardware and software. It develops a prototype of the Nanox.ARC, a medical imaging system incorporating its novel digital X-ray source; and Nanox.CLOUD, a companion cloud-based software that will allow for the delivery of medical screening as a service. It has three business segments: Nanox.ARC division, the radiology services division and the AI solutions division. Key revenue is generated from Radiology Services.